Golden State Equity Partners Cyma Bay Therapeutics, Inc. Transaction History

Golden State Equity Partners

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 02, 2024	BUY	$12.63 - $24.47 $54,170 - $104,951	4,289 Added 8.58%	54,289 $1.28 Million
Q1 2023 Jun 01, 2023	SELL	$5.88 - $9.59 $3,528 - $5,754	-600 Reduced 1.19%	50,000 $436 Million
Q1 2022 May 18, 2022	BUY	$2.77 - $3.64 $140,162 - $184,184	50,600 New	50,600 $157,000
Q1 2022 May 16, 2022	SELL	$2.77 - $3.64 $139,885 - $183,820	-50,500 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$3.23 - $4.6 $57,009 - $81,190	17,650 Added 53.73%	50,500 $171,000
Q3 2021 Nov 15, 2021	BUY	$3.47 - $4.42 $113,989 - $145,197	32,850 New	32,850 $120,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

Stay updated on Golden State Equity Partners with notifications on news.